Inari Medical (NARI) said Tuesday that treatment with FlowTriever showed superiority compared with catheter-directed thrombolytics or CDT in a randomized study that enrolled 550 intermediate-risk pulmonary embolism patients.
The company said the study achieved its primary composite endpoint, with patients experiencing three times fewer clinical deteriorations and/or therapy escalations, and "significantly less" intensive care unit admission and length of stay with FlowTriever compared with CDT.
Inari shares advanced more than 10% in recent trading.
Price: 46.96, Change: +4.40, Percent Change: +10.34
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments